Physician profile
Fred MD Lui
NPI 1265461644
$68,307.57
in general payments reported to CMS, 2019-2025
28 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $67.75 · 2021: $136 · 2022: $16K · 2023: $15K · 2024: $16K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $50K · Food and Beverage: $2,371 · Travel and Lodging: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $49,750.00 |
| Food and Beverage | $2,370.76 |
| Travel and Lodging | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $64,750.00 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Astrazeneca Pharmaceuticals LP | $810.60 | 2021-2025 | Calquence, Lokelma, Tagrisso |
| Akebia Therapeutics INC | $254.29 | 2019-2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $239.50 | 2020-2025 | Fruzaqla |
| Janssen Pharmaceuticals, INC | $225.20 | 2022-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $214.43 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $193.17 | 2022-2025 | |
| Amgen INC. | $173.92 | 2022-2024 | Tavneos, Aranesp, Parsabiv |
| Rigel Pharmaceuticals, INC. | $146.73 | 2022-2023 | Tavalisse, Rezlidhia |
| Otsuka America Pharmaceutical, INC. | $133.15 | 2019 | |
| Agios Pharmaceuticals, INC. | $131.84 | 2024-2025 | Pyrukynd |
| Nxstage Medical, INC. | $130.77 | 2025 | Nxstage System One, Liberty Select Cycler |
| Travere Therapeutics, INC. | $123.06 | 2024-2025 | |
| Novo Nordisk INC | $109.62 | 2025 | Ozempic |
| Gilead Sciences, INC. | $109.58 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $103.49 | 2022 | |
| Janssen Biotech, INC. | $72.65 | 2023-2025 | Rybrevant, Akeega, Balversa |
| Coherus Oncology, INC. | $71.69 | 2024 | |
| Merck Sharp & Dohme LLC | $62.76 | 2025 | Keytruda |
| Eisai INC. | $52.78 | 2024-2025 | |
| Geron Corporation | $33.19 | 2024 | Rytelo |
| Astellas Pharma US INC | $31.26 | 2023 | |
| Novartis Pharmaceuticals Corporation | $26.76 | 2025 | |
| Aurinia Pharma U.S., INC. | $25.91 | 2021 | |
| Morphosys, US INC. | $24.75 | 2022 | |
| Exact Sciences Corporation | $22.15 | 2025 | Cologuard Collection Kit |
| Novocure INC. | $19.32 | 2025 | Optune Lua (Novottf-200t) |
| Daiichi Sankyo INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Lui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.